XML 132 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

Capital Stock, Stock Plans, Warrants and Stock Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2021
Share-based Payment Arrangement [Abstract] |
Capital Stock, Stock Plans,Warrants, and Stock Based Compensation |
6. | Capital Stock, Stock Plans, Warrants and Stock Based Compensation
The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants. No stock options were granted in the first quarter of 2021. The Company granted a NQSO to Robert Ferguson on July 27, 2017 from the Company’s 2017 Stock Option Plan (“2017 Plan”) for the purchase of up to 100,000 shares of the Company’s Common Stock (“Ferguson Stock Option”) in connection with his work as a consultant to the Company’s Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility at an exercise price of $3.65 per share, which was the fair market value of the Company’s Common Stock on the date of grant. The term of the Ferguson Stock Option is seven years from the grant date. The vesting of the Ferguson Stock Option is subject to the achievement of three separate milestones by certain dates. The 10,000 options under the first milestone were exercised by Robert Ferguson in 2018. The vesting date for the second and third milestones for the purchase of up to 30,000 and 60,000 shares of the Company’s Common Stock was previously extended to December 31, 2021 and December 31, 2022, respectively. The Company has not recognized compensation costs (fair value of approximately $262,000 at March 31, 2021) for the remaining 90,000 Ferguson Stock Option under the remaining two milestones since achievement of the performance obligation under each of the two remaining milestones is uncertain at March 31, 2021. All other terms of the Ferguson Stock Option remain unchanged. The following table summarizes stock-based compensation recognized for the three months ended March 31, 2021 and 2020 for our employee and director stock options.
|  | Three Months Ended |
Stock Options |  | March 31, |
|  | 2021 |  |  | 2020 |
Employee Stock Options |  | $ | 33,000 |  |  | $ | 32,000 |
Director Stock Options |  |  | 12,000 |  |  |  | 12,000 |
Total |  | $ | 45,000 |  |  | $ | 44,000 |
At March 31, 2021, the Company has approximately $229,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately 2.0 years. The summary of the Company’s total Stock Option Plans as of March 31, 2021 and March 31, 2020, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan, the 2017 Plan and the 2003 Outside Directors Stock Plan (“2003 Plan”):
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (3) |
Options outstanding January 1, 2021 |  |  | 658,400 |  |  | $ | 3.87 |  |  |  |  |  |  |  |  |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  |  | — |  |  |  |  |  |  |  | — |
Forfeited/expired |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Options outstanding end of period (1) |  |  | 658,400 |  |  | $ | 3.87 |  |  |  | 3.2 |  |  | $ | 2,279,267 |
Options exercisable at March 31, 2021(1) |  |  | 392,400 |  |  | $ | 4.08 |  |  |  | 3.4 |  |  | $ | 1,274,287 |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (years) |  |  | Aggregate Intrinsic Value (3) |
Options outstanding January 1, 2020 |  |  | 681,300 |  |  | $ | 3.84 |  |  |  |  |  |  |  |  |
Granted |  |  | 6,000 |  |  |  | 7.00 |  |  |  |  |  |  |  |  |
Exercised |  |  | (12,000 | ) |  |  | 3.48 |  |  |  |  |  |  |  | 14,600 |
Forfeited/expired |  |  | (20,000 | ) |  |  | 3.45 |  |  |  |  |  |  |  |  |
Options outstanding end of period (2) |  |  | 655,300 |  |  | $ | 3.88 |  |  |  | 4.0 |  |  | $ | 962,189 |
Options exercisable at March 31, 2020(2) |  |  | 306,800 |  |  | $ | 4.20 |  |  |  | 3.9 |  |  | $ | 392,614 |
(1) Options with exercise prices ranging from $2.79 to $7.29 (2) Options with exercise prices ranging from $2.79 to $8.40 (3) The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the option. During the three months ended March 31, 2021, the Company issued a total of 11,837 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board of Directors (the “Board”). The Company recorded approximately $107,000 in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors. See “Note 16 – Subsequent Events - 2003 Plan” for a discussion of a proposed amendment to the 2003 Plan as approved by the Company’s Board of Directors (the “Board”), subject to the approval by the Company’s Stockholder at the Company’s 2021 Annual Meeting of Stockholders to be held on July 20, 2021. In connection with a $2,500,000 loan that the Company entered into with Mr. Robert Ferguson (the “Ferguson Loan”) on April 1, 2019, the Company issued a warrant to Mr. Ferguson for the purchase of up to 60,000 shares of our Common Stock at an exercise price of $3.51 per share. The warrant is exercisable six months from April 1, 2019 and expires on April 1, 2024 and remains outstanding at March 31, 2021. The Ferguson Loan was paid-in-full in December 2020.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration